A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent

Trial Profile

A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 275
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 21 Sep 2017 The trial has been completed in Finland.
    • 12 Sep 2017 Results of an exploratory analysis assesing the potential association between pretreatment tumor mutation burden (TMB) and response to nivolumab, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results assessing impact of epithelial-mesenchymal transition (EMT), T cell infiltration on outcomes with PD-1/PD-L1 blockade in CheckMate 275 trial, presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top